Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers

REFERENCES

1. 1.↵
   1. Duker AP,
   2. Espay AJ,
   3. Wszolek ZK,
   4. et al

   . Atypical motor and behavioral presentations of Alzheimer disease: a case-based approach. Neurologist 2012;18:266–72

   CrossRefPubMed
2. 2.↵
   1. Murray ME,
   2. Graff-Radford NR,
   3. Ross OA,
   4. et al

   . Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785–96

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Holland D,
   2. Desikan RS,
   3. Dale AM,
   4. et al

   . Rates of decline in Alzheimer disease decrease with age. PLoS One 2012;7:e42325

   CrossRefPubMed
4. 4.↵
   1. van der Flier WM,
   2. Pijnenburg YA,
   3. Fox NC,
   4. et al

   . Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol 2011;10:280–88

   CrossRefPubMedWeb of Science
5. 5.↵
   Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013;9:208–45

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Miech RA,
   2. Breitner JC,
   3. Zandi PP,
   4. et al

   . Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002;58:209–18

   CrossRef
7. 7.↵
   1. Farrer LA,
   2. Cupples LA,
   3. Haines JL,
   4. et al

   . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349–56

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Seshadri S,
   2. Wolf PA,
   3. Beiser A,
   4. et al

   . Lifetime risk of dementia and Alzheimer's disease: the impact of mortality on risk estimates in the Framingham Study. Neurology 1997;49:1498–504

   CrossRef
9. 9.↵
   1. Andersen K,
   2. Launer LJ,
   3. Dewey ME,
   4. et al

   . Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies: EURODEM Incidence Research Group. Neurology 1999;53:1992–97

   CrossRef
10. 10.↵
    1. Plassman BL,
    2. Langa KM,
    3. McCammon RJ,
    4. et al

    . Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol 2011;70:418–26

    CrossRefPubMed
11. 11.↵
    1. Breitner JC,
    2. Wyse BW,
    3. Anthony JC,
    4. et al

    . APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999;53:321–31

    CrossRef
12. 12.↵
    1. Barnes LL,
    2. Wilson RS,
    3. Schneider JA,
    4. et al

    . Gender, cognitive decline, and risk of AD in older persons. Neurology 2003;60:1777–81

    CrossRef
13. 13.↵
    1. Hebert LE,
    2. Scherr PA,
    3. McCann JJ,
    4. et al

    . Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol 2001;153:132–36

    Abstract/FREE Full Text
14. 14.↵
    1. Ghebremedhin E,
    2. Schultz C,
    3. Thal DR,
    4. et al

    . Gender and age modify the association between APOE and AD-related neuropathology. Neurology 2001;56:1696–701

    CrossRef
15. 15.↵
    1. Irvine K,
    2. Laws KR,
    3. Gale TM,
    4. et al

    . Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 2012;34:989–98

    CrossRefPubMed
16. 16.↵
    1. Corder EH,
    2. Saunders AM,
    3. Strittmatter WJ,
    4. et al

    . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921–23

    Abstract/FREE Full Text
17. 17.↵
    1. Verghese PB,
    2. Castellano JM,
    3. Holtzman DM

    . Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011;10:241–52

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Sando SB,
    2. Melquist S,
    3. Cannon A,
    4. et al

    . APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease: a case control study from central Norway. BMC Neurol 2008;8:9

    CrossRefPubMed
19. 19.↵
    1. Khachaturian AS,
    2. Corcoran CD,
    3. Mayer LS,
    4. et al

    . Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry 2004;61:518–24

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Corder EH,
    2. Saunders AM,
    3. Strittmatter WJ,
    4. et al

    . Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323–28

    CrossRef
21. 21.↵
    1. Holland D,
    2. McEvoy LK,
    3. Dale AM

    . Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp 2012;33:2586–602

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Holland D,
    2. Dale AM

    . Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489–97

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Holland D,
    2. McEvoy LK,
    3. Desikan RS,
    4. et al

    . Enrichment and stratification for predementia Alzheimer disease clinical trials. PloS One 2012;7:e47739

    CrossRefPubMed
24. 24.↵
    1. Arriagada PV,
    2. Marzloff K,
    3. Hyman BT

    . Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681–88

    CrossRef
25. 25.↵
    1. Arnold SE,
    2. Hyman BT,
    3. Flory J,
    4. et al

    . The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103–16

    Abstract/FREE Full Text
26. 26.↵
    1. Braak H,
    2. Braak E

    . Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351–57

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Williams MM,
    2. Storandt M,
    3. Roe CM,
    4. et al

    . Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement 2013;9(1 Suppl):S39–44

    CrossRefPubMed
28. 28.↵
    1. Morris JC

    . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–14

    CrossRefPubMed
29. 29.↵
    1. Rosen WG,
    2. Mohs RC,
    3. Davis KL

    . A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–64

    PubMedWeb of Science
30. 30.↵
    1. Rockwood K,
    2. Fay S,
    3. Gorman M,
    4. et al

    . The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol 2007;7:26

    CrossRefPubMed
31. 31.↵
    1. Folstein MF,
    2. Folstein SE,
    3. McHugh PR

    . “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Fitzmaurice GM,
    2. Laird NM,
    3. Ware JH

    . Applied Longitudinal Analysis. Hoboken, New Jersey: Wiley; 2011
33. 33.↵
    1. Bernick C,
    2. Cummings J,
    3. Raman R,
    4. et al

    . Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 2012;69:901–05

    CrossRefPubMed
34. 34.↵
    1. Plassman BL,
    2. Langa KM,
    3. Fisher GG,
    4. et al

    . Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29:125–32

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Corder EH,
    2. Ghebremedhin E,
    3. Taylor MG,
    4. et al

    . The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 2004;1019:24–28

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Yaffe K,
    2. Haan M,
    3. Byers A,
    4. et al

    . Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000;54:1949–54

    CrossRef
37. 37.↵
    1. Xu H,
    2. Gouras GK,
    3. Greenfield JP,
    4. et al

    . Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998;4:447–51

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Prince JA,
    2. Zetterberg H,
    3. Andreasen N,
    4. et al

    . APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004;62:2116–18

    CrossRef
39. 39.↵
    1. Kester MI,
    2. Blankenstein MA,
    3. Bouwman FH,
    4. et al

    . CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 2009;16:601–07

    PubMedWeb of Science
40. 40.↵
    1. Walker LC,
    2. Pahnke J,
    3. Madauss M,
    4. et al

    . Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol 2000;100:36–42

    CrossRefPubMed
41. 41.↵
    1. Koffie RM,
    2. Hashimoto T,
    3. Tai HC,
    4. et al

    . Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 2012;135:2155–68

    Abstract/FREE Full Text
42. 42.↵
    1. DeKosky ST,
    2. Scheff SW

    . Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457–64

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Van Hoesen GW,
    2. Parvizi J,
    3. Chu CC

    . Orbitofrontal cortex pathology in Alzheimer's disease. Cereb Cortex 2000;10:243–51

    Abstract/FREE Full Text
44. 44.↵
    1. Saunders AM

    . Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol 2000;59:751–58

    PubMedWeb of Science
45. 45.↵
    1. Growdon JH,
    2. Locascio JJ,
    3. Corkin S,
    4. et al

    . Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444–48

    CrossRef
46. 46.↵
    1. Cosentino S,
    2. Scarmeas N,
    3. Helzner E,
    4. et al

    . APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008;70:1842–49
47. 47.↵
    1. Juva K,
    2. Verkkoniemi A,
    3. Viramo P,
    4. et al

    . APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412–15

    CrossRef
48. 48.↵
    1. Hyman BT

    . Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062–64

    CrossRefPubMedWeb of Science